MarketPulse

psilocybin

5 articles
The Motley FoolThe Motley Fool··Howard Smith

Compass Pathways Surges 40% on White House Push for Psychedelic Drug Approvals

Compass Pathways stock surges 40% following White House Executive Order accelerating FDA approval of its COMP360 psychedelic therapy for treatment-resistant depression.
CMPSFDA approvaltreatment-resistant depression
The Motley FoolThe Motley Fool··Motley Fool Staff

Psychedelic Therapy Emerges as Disruptive Mental Health Treatment Model

Psychedelic therapy advances as clinical treatment for depression and PTSD, with companies like Compass Pathways pursuing FDA approvals. The investment opportunity centers on $10,000-$20,000 treatment services rather than drugs.
JNJABBVCMPStreatment-resistant depressionpsilocybin
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Psyence BioMed Executes Put Option, Issues $5M in Shares to PsyLabs

Psyence BioMed issues $5M in shares to PsyLabs via put option exercise, giving PsyLabs ~50% ownership and strengthening supply chain for psychedelic pharmaceuticals.
PBMPBMWWsupply chainshareholder dilution
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Psyence BioMed Secures Psychedelic Supply via Put Option Deal with PsyLabs

Psyence BioMed secures pharmaceutical-grade psychedelic supply through put option deal with PsyLabs, ensuring reliable access while maintaining liquidity for clinical development.
PBMPBMWWsupply chainpsilocybin